CA-ANDERSEN-GLOBAL
Andersen Global forener sin platform i Nordamerika, idet dets medlemsfirmaer i Canada antager brandet, "Andersen", hvilket afspejler organisationens evne til at levere en komplet pakke med integrerede tjenester gennem sine medlems- og samarbejdsfirmaer over hele verden.
De canadiske medlemsfirmaer, der tidligere drev virksomhed under navnet Andersen Tax, deler nu det fælles brand "Andersen" med det amerikanske medlemsfirma på regional basis, sammen med medlemsfirmaer over hele verden i Europa, Latinamerika, Mellemøsten og Afrika. Det amerikanske medlemsfirma skiftede til Andersen-brandet i 2019, hvilket startede den globale antagelse af navnet af organisationens medlemsfirmaer i 2020 og begyndelsen af 2021.
"Denne forening under et fælles brand demonstrerer vores fælles kultur, værdier og vores forpligtelse til at betjene vores kunder på en sømløs måde over hele verden," sagde bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz. "Dette er et vigtigt skridt i vores globale organisations udvikling, idet vi fortsætter med at udvide og styrke vores globale platform."
Grundlagt i 2002 af 23 tidligere skattepartnere fra Arthur Andersen, startede Andersen sin rejse som WTAS LLC, et selskab, der kun leverede skattetjenester, som etablerede WTAS Global i 2013. Det stiftende amerikanske medlemsfirma begyndte derefter at drive virksomhed som Andersen Tax i 2014, og den globale organisation blev kendt som Andersen Global. Den globale organisation trådte ind på det canadiske marked i 2016 og driver nu virksomhed med fem partnere og næsten 40 eksperter på kontorer i Montreal, Vancouver, Calgary og Edmonton.
"Vi mener, at dette er en milepæl, der styrker de værdier og visioner, der forbliver kernen i vores firma, både lokalt og globalt," sagde administrerende direktør hos Andersen i Montreal, Simon Davari. "Denne overgang understøtter vores vækst og udvikling, fremhæver bredden og dybden af vores ekspertise og styrker vores position på det canadiske marked."
Warren Dueck, administrerende direktør hos Andersen i Vancouver, tilføjede: "I løbet af de sidste par år er vores firma vokset markant, og dets udvikling fremhæver vores 'one firm'-kultur, da vi arbejder sømløst med at bygge videre på det eksisterende fundament for Andersen-brandet i Nordamerika sammen med vores kolleger i USA. Idet vi ser frem mod dette næste trin i vores firmas udvikling, forbliver vores team dedikeret til at levere uovertrufne tjenester til kunder, især hvad angår amerikanske og canadiske grænseoverskridende skattetjenester."
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Efter at være blevet etableret i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 7.000 eksperter globalt og er repræsenteret på mere end 261 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210324005403/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
